Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003080916 | SCV003487059 | uncertain significance | Congenital dyserythropoietic anemia, type II; Cowden syndrome 7 | 2022-07-11 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 205 of the SEC23B protein (p.Gly205Ala). This variant is present in population databases (rs762101557, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SEC23B-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV003481393 | SCV004225466 | uncertain significance | not provided | 2022-05-02 | criteria provided, single submitter | clinical testing | PM2 |
Ambry Genetics | RCV004961051 | SCV005502522 | uncertain significance | Inborn genetic diseases | 2024-09-11 | criteria provided, single submitter | clinical testing | The c.614G>C (p.G205A) alteration is located in exon 6 (coding exon 5) of the SEC23B gene. This alteration results from a G to C substitution at nucleotide position 614, causing the glycine (G) at amino acid position 205 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |